Nifurtimox

Chagas Disease (T. cruzi Infection) Market: Comprehensive Global Analysis and Forecast Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Infectious Diseases, Pharmaceutical, Health, Pharmacy, Intelligence, Chagas disease, FDA, Infection, Epidemiology, ESG, Hospital, Health care, Bayer, Child, CDC, Movement, Trypanosoma cruzi, Research report, Nifurtimox, Vaccine

The protozoan Trypanosoma cruzi is the cause of Chagas disease (CD), also known as American trypanosomiasis, a chronic, systemic, parasitic illness with substantial risk factors associated with low socioeconomic status.

Key Points: 
  • The protozoan Trypanosoma cruzi is the cause of Chagas disease (CD), also known as American trypanosomiasis, a chronic, systemic, parasitic illness with substantial risk factors associated with low socioeconomic status.
  • It is widespread throughout 21 American countries, but it can spread to non-endemic nations worldwide through the movement of infected individuals.
  • The research report provides a thorough overview of the Chagas Disease market.
  • This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis.

U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children

Retrieved on: 
Friday, August 7, 2020
General Health, FDA, Infectious diseases, Health, Pharmaceutical, Infectious diseases, Medical specialties, RTT, Antiprotozoal agents, Neglected tropical diseases, Chagas disease, Nifurtimox, Chagas, General Health, FDA, Infectious diseases, Health, Pharmaceutical, Infectious diseases, Medical specialties, RTT, Antiprotozoal agents, Neglected tropical diseases, Chagas disease, Nifurtimox, Chagas

The importance of treating children is a major reason behind Bayers collaboration with health authorities to enhance access to Lampit as a means to provide treatment for Chagas disease.

Key Points: 
  • The importance of treating children is a major reason behind Bayers collaboration with health authorities to enhance access to Lampit as a means to provide treatment for Chagas disease.
  • The FDA approval is based on results from the Chagas disease in children treated with nifurtimox study, the first part of the largest Phase III program ever conducted in pediatric patients for the treatment of Chagas disease.
  • The hypersensitivity could be a reaction induced by nifurtimox or an immune response triggered by Chagas disease during treatment.
  • Making treatment safer and more effective for people living with Chagas disease: an update on DNDis Chagas disease portfolio.

Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients With Chagas Disease Meets Primary Endpoint

Retrieved on: 
Thursday, March 14, 2019
Infectious diseases, RTT, Chemistry, Medical specialties, Antiprotozoal agents, Nifurtimox, Benznidazole, Chagas disease, Carlos Chagas, Chagas

WHIPPANY, N.J., March 14, 2019 /PRNewswire/ --Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the "XV Taller sobre la enfermedad de Chagas" conference in Barcelona, Spain.

Key Points: 
  • WHIPPANY, N.J., March 14, 2019 /PRNewswire/ --Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with Chagas disease at the "XV Taller sobre la enfermedad de Chagas" conference in Barcelona, Spain.
  • CHICO was the first part of a prospective, randomized (to dosing regimen), double-blind, historically placebo controlled phase III trial to evaluate the efficacy, safety, and pharmacokinetics of nifurtimox in 330 pediatric patients with acute or chronic Chagas disease.
  • The treatment of Chagas disease is based on only two nitroheterocyclic compounds, nifurtimox and benznidazole.
  • Chagas disease is named after Carlos Ribeiro Justiniano Chagas, a Brazilian physician and researcher who discovered the disease in 1909.

Chagas Disease (American Trypanosomiasis): Global Clinical Trials Review, H2, 2018 - Top Level Data by Region, Country, Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 13, 2019
Health, Clinical trials, Infectious diseases, Pharmaceutical, Infectious diseases, Health, Medical specialties, Clinical research, Pharmaceutical industry, RTT, Neglected diseases, Tropical diseases, Chagas disease, Clinical trial, Nifurtimox

The "Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering.
  • Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2018 provides an overview of Chagas Disease (American Trypanosomiasis) clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Chagas Disease.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.